Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 5, 2000, Pages 625-634

  Annibale, B ^a   Aprile, M Rosaria ^b   D'Ambra, G ^b   Caruana, P ^b   Bordi, C ^b   Fave, G Delle ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACID; AMOXICILLIN; BISMUTH CITRATE; GASTRIN; METRONIDAZOLE; PEPSINOGEN I;

ADULT; AGED; ARTICLE; ATROPHIC GASTRITIS; CELL HYPERPLASIA; CELL PROLIFERATION; ENDOCRINE CELL; FEMALE; GASTRIN BLOOD LEVEL; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HELICOBACTER PYLORI INFECTION; HISTOLOGY; HUMAN; HYPERGASTRINEMIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; TREATMENT OUTCOME;

ADULT; AGED; ENTEROCHROMAFFIN CELLS; FEMALE; GASTRIC MUCOSA; GASTRINS; GASTRITIS, ATROPHIC; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; HYPERPLASIA; MALE; MIDDLE AGED; PEPSINOGEN A; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034094601     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00752.x     Document Type: Article

References (38)

1. 1 Whittingham S, Mackay IR. Pernicious anemia and gastric atrophy. In: Rose NR, Mackay IR, eds. The Autoimmune Diseases. Orlando, Fl: Academic. 1985: 243-66.
2. 2 Strickland RG, Mackay IRA. Reappraisal, significance of chronic atrophic gastritis. Dig Dis 1973; 18: 426-40.
3. 3 Appelman HD. Gastritis: terminology etiology, clinicopathological correlations: Another biased view. Human Pathol 1994; 25: 1006-19.
4. 4 Maton PN. Gastrinoma and Other Hypergastrinemic Syndromes. In: Walsh JH, Dockrey GJ, eds. Gut Peptides: Biochemistry and Physiology. New York: Raven Press, 1994: 675-700.
5. 5 Fong TL, Dooley CP, Dehesa M, et al. Helicobacter pylori infection in pernicious anemia: a prospective controlled study. Gastroenterology 1991; 100: 328-32.
6. 6 Karnes WE, Samloff IM, Siurala M, et al. Positive serum antibody, negative issue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167-74.
7. 7 El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection, chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 15-24.
8. 8 Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelac of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-28.
9. 9 Annibale B, Marignani M, Azzoni C, et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997; 2: 57-64.
10. 10 Tucci A, Biasco G, Paparo GF. Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis. N Eng J Med 1997; 336: 957-58.
11. 11 Bordi C, Annibale B, Azzoni C, et al. Endocrine cell growths in atrophic body gastritis. Critical evaluation of a histological classification. J Pathol 1997; 182: 339-346.
12. 12 Weinstein WM. Gastritis and gastropathies. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease, 5th edn. Philadelphia: Saunders, 1993: 545-71.
13. 13 Correa P. Chronic gastritis: a clinic-pathological classification. Am J Gastroenterol 1988; 83: 504.
14. 14 Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996; 20: 1161-81.
15. 15 Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988: 41: 185-200.
16. 16 Genta RM, Ginger ML, Graham DY. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod Pathol 1993; 6: 281-9.
17. 17 Delle Fave G, Kohn A, de Magistris L, et al. Effects of bombesin on gastrin and gastric acid secretion in patients with duodenal ulcer. Gut 1983; 24: 231-5.
18. 18 Annibale B, de Magistris L, Corleto V, et al. Zollinger-Ellison syndrome and antral G-cell hyperfunction in patients with resistant duodenal ulcer disease. Aliment Pharmacol Ther 1994: 8: 87-93.
19. 19 Tucci A, Poli L, Tosetti G, et al. Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol 1998; 93: 1425-31.
20. 20 Unge P. What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 1997; 113: S131-48.
21. 21 Faisal MA, Russell RM, Samloff IM, et al. Helicobacter pylori infection and atrophic gastritis in the elderly. Gastroenterology 1990; 99: 1543-4.
22. 22 Oberhuber G, Wuendisch T, Rappel S, et al. Significant improvement of atrophy after eradication therapy in atrophic body gastritis. Pathol Res Pract 1998; 194: 609-13.
23. 23 Haruma K, Mihara M, Okamoto E, et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus - evaluation of 24-h pH monitoring Aliment Pharmacol Ther 1999; 13: 155-62.
24. 24 Satoh K, Kimura K, Takimoto T, et al. A follow-up study of atrophic gastritis and intestinal metaplasia after the eradication of Helicobacter pylori. Helicobacter 1998; 3: 236-40.
25. 25 Genta RM. Helicobacter pylori, inflammation, mucosal damage and apoptosis: Pathogenesis and definition of gastric atrophy. Gastroenterology 1997; 113: S51-5.
26. 26 Domellof L. Reversal of gastric atrophy after Helicobacter pylori eradication: is it possible or not. Am J Gastroenterol 1998; 93: 1407-8.
27. 27 Samloff IM, Varis K, Ihamaki T, et al. Relationship among serum pepsinogen I, serum pepsinogen II and gastric mucosal history. A study in relatives of patients with pernicious anemia. Gastroenterology 1982; 83: 204-9.
28. 28 Feldman M, Cryer B, McArthur CE, et al. Effects of ageing and gastritis on gastric acid and pepsin secretion in human: a prospective study. Gastroenterology 1996; 110: 1043-52.
29. 29 Kondo S, Shimura Y, Kanayama S, et al. Interleukin 1 beta inhibits gastric histamine secretion and synthesis in rat. Am J Physiol 1994; 267: G966-71.
30. 30 Yasunaga Y, Shinomura Y, Kanayama S, et al. Mucosal interleukin 1 beta production and acid secretion in enlarged fold gastritis. Aliment Pharmacol Ther 1997; 11: 801-9.
31. 31 Taguchi Y, Kaito M, Gabazza EC, et al. Helicobacter pylori inhibits the secretory activity of gastric parietal cells in patients with chronic gastritis. Scand J Gastroenterol 1997; 32: 656-63.
32. 32 Furuta T, Baba S, Takashima M, et al. Effect of Helicobacter pylori infection on gastric juice pH. Scand J Gastroenterology 1998; 33: 357-63.
33. 33 Feldman M, Cryer B, Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol (Gastroenterol) 1998; 274: G1011-7.
34. 34 Ruìz B, Correa P, Fonthman ET, et al. Antral atrophy, Helicobacter pylori colonization, and gastric pH. Am J Clin Pathol 1996; 105: 96-101.
35. 35 McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutics implications. Gastroenterology 1996; 110: 926-38.
36. 36 D'Adda T, Annibale B, Delle Fave G, et al. Oxyntic endocrine cells of hypergastrimenic patients. Differential responses to antrectomy or octreotide. Gut 1996; 38: 668-74.
37. 37 Ferraro G, Annibale B, Marignani M, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocr Metab 1996; 81: 677-83.
38. 38 Sjoblom SM, Sipponen P, Jarvinen H. Gastroscopic follow-up of pernicious anemia patients. Gut 1993; 34: 28-32.